Literature DB >> 29536161

Genetic risk factors in Parkinson's disease.

K J Billingsley1,2, S Bandres-Ciga1, S Saez-Atienzar1, A B Singleton3.   

Abstract

Over the last two decades, we have witnessed a revolution in the field of Parkinson's disease (PD) genetics. Great advances have been made in identifying many loci that confer a risk for PD, which has subsequently led to an improved understanding of the molecular pathways involved in disease pathogenesis. Despite this success, it is predicted that only a relatively small proportion of the phenotypic variability has been explained by genetics. Therefore, it is clear that common heritable components of disease are still to be identified. Dissecting the genetic architecture of PD constitutes a critical effort in identifying therapeutic targets and although such substantial progress has helped us to better understand disease mechanism, the route to PD disease-modifying drugs is a lengthy one. In this review, we give an overview of the known genetic risk factors in PD, focusing not on individual variants but the larger networks that have been implicated following comprehensive pathway analysis. We outline the challenges faced in the translation of risk loci to pathobiological relevance and illustrate the need for integrating big-data by noting success in recent work which adopts a broad-scale screening approach. Lastly, with PD genetics now progressing from identifying risk to predicting disease, we review how these models will likely have a significant impact in the future.

Entities:  

Keywords:  Common risk factors; Genetics; Genome-wide association study; Parkinson’s disease; Prediction

Mesh:

Year:  2018        PMID: 29536161      PMCID: PMC6201690          DOI: 10.1007/s00441-018-2817-y

Source DB:  PubMed          Journal:  Cell Tissue Res        ISSN: 0302-766X            Impact factor:   5.249


  84 in total

Review 1.  The role of ATP13A2 in Parkinson's disease: Clinical phenotypes and molecular mechanisms.

Authors:  Jin-Sung Park; Nicholas F Blair; Carolyn M Sue
Journal:  Mov Disord       Date:  2015-04-21       Impact factor: 10.338

2.  Collaborative analysis of alpha-synuclein gene promoter variability and Parkinson disease.

Authors:  Demetrius M Maraganore; Mariza de Andrade; Alexis Elbaz; Matthew J Farrer; John P Ioannidis; Rejko Krüger; Walter A Rocca; Nicole K Schneider; Timothy G Lesnick; Sarah J Lincoln; Mary M Hulihan; Jan O Aasly; Tetsuo Ashizawa; Marie-Christine Chartier-Harlin; Harvey Checkoway; Carlo Ferrarese; Georgios Hadjigeorgiou; Nobutaka Hattori; Hideshi Kawakami; Jean-Charles Lambert; Timothy Lynch; George D Mellick; Spiridon Papapetropoulos; Abbas Parsian; Aldo Quattrone; Olaf Riess; Eng-King Tan; Christine Van Broeckhoven
Journal:  JAMA       Date:  2006-08-09       Impact factor: 56.272

3.  Association of an extended haplotype in the tau gene with progressive supranuclear palsy.

Authors:  M Baker; I Litvan; H Houlden; J Adamson; D Dickson; J Perez-Tur; J Hardy; T Lynch; E Bigio; M Hutton
Journal:  Hum Mol Genet       Date:  1999-04       Impact factor: 6.150

4.  Occurrence of Parkinson's syndrome in type I Gaucher disease.

Authors:  O Neudorfer; N Giladi; D Elstein; A Abrahamov; T Turezkite; E Aghai; A Reches; B Bembi; A Zimran
Journal:  QJM       Date:  1996-09

5.  Impact of Parkinson's disease risk loci on age at onset.

Authors:  Christina M Lill; Johnni Hansen; Jørgen H Olsen; Harald Binder; Beate Ritz; Lars Bertram
Journal:  Mov Disord       Date:  2015-04-25       Impact factor: 10.338

6.  Linkage disequilibrium and association of MAPT H1 in Parkinson disease.

Authors:  Lisa Skipper; Kristen Wilkes; Mathias Toft; Matthew Baker; Sarah Lincoln; Mary Hulihan; Owen A Ross; Mike Hutton; Jan Aasly; Matthew Farrer
Journal:  Am J Hum Genet       Date:  2004-08-03       Impact factor: 11.025

Review 7.  Genetics in Parkinson disease: Mendelian versus non-Mendelian inheritance.

Authors:  Dena G Hernandez; Xylena Reed; Andrew B Singleton
Journal:  J Neurochem       Date:  2016-04-18       Impact factor: 5.372

8.  Integrated molecular landscape of Parkinson's disease.

Authors:  J E Visser; G Poelmans; C J H M Klemann; G J M Martens; M Sharma; M B Martens; O Isacson; T Gasser
Journal:  NPJ Parkinsons Dis       Date:  2017-04-10

9.  The Parkinson's disease-linked proteins Fbxo7 and Parkin interact to mediate mitophagy.

Authors:  Victoria S Burchell; David E Nelson; Alvaro Sanchez-Martinez; Marta Delgado-Camprubi; Rachael M Ivatt; Joe H Pogson; Suzanne J Randle; Selina Wray; Patrick A Lewis; Henry Houlden; Andrey Y Abramov; John Hardy; Nicholas W Wood; Alexander J Whitworth; Heike Laman; Helene Plun-Favreau
Journal:  Nat Neurosci       Date:  2013-08-11       Impact factor: 24.884

10.  Unbiased screen for interactors of leucine-rich repeat kinase 2 supports a common pathway for sporadic and familial Parkinson disease.

Authors:  Alexandria Beilina; Iakov N Rudenko; Alice Kaganovich; Laura Civiero; Hien Chau; Suneil K Kalia; Lorraine V Kalia; Evy Lobbestael; Ruth Chia; Kelechi Ndukwe; Jinhui Ding; Mike A Nalls; Maciej Olszewski; David N Hauser; Ravindran Kumaran; Andres M Lozano; Veerle Baekelandt; Lois E Greene; Jean-Marc Taymans; Elisa Greggio; Mark R Cookson
Journal:  Proc Natl Acad Sci U S A       Date:  2014-02-07       Impact factor: 11.205

View more
  64 in total

Review 1.  Genetics of Parkinson's disease: An introspection of its journey towards precision medicine.

Authors:  Sara Bandres-Ciga; Monica Diez-Fairen; Jonggeol Jeff Kim; Andrew B Singleton
Journal:  Neurobiol Dis       Date:  2020-01-25       Impact factor: 5.996

Review 2.  Mechanisms of PINK1, ubiquitin and Parkin interactions in mitochondrial quality control and beyond.

Authors:  Andrew N Bayne; Jean-François Trempe
Journal:  Cell Mol Life Sci       Date:  2019-06-28       Impact factor: 9.261

Review 3.  The role of Rab GTPases in the pathobiology of Parkinson' disease.

Authors:  Luis Bonet-Ponce; Mark R Cookson
Journal:  Curr Opin Cell Biol       Date:  2019-05-01       Impact factor: 8.382

Review 4.  Endosomal Trafficking in Alzheimer's Disease, Parkinson's Disease, and Neuronal Ceroid Lipofuscinosis.

Authors:  Yasir H Qureshi; Penelope Baez; Christiane Reitz
Journal:  Mol Cell Biol       Date:  2020-09-14       Impact factor: 4.272

5.  Frequency of the LRRK2 G2019S mutation in South African patients with Parkinson's disease.

Authors:  Nicola du Toit; Riaan van Coller; David G Anderson; Jonathan Carr; Soraya Bardien
Journal:  Neurogenetics       Date:  2019-09-06       Impact factor: 2.660

Review 6.  Triggers, Facilitators, and Aggravators: Redefining Parkinson's Disease Pathogenesis.

Authors:  Michaela E Johnson; Benjamin Stecher; Viviane Labrie; Lena Brundin; Patrik Brundin
Journal:  Trends Neurosci       Date:  2018-10-17       Impact factor: 13.837

Review 7.  Immune Signaling in Neurodegeneration.

Authors:  Timothy R Hammond; Samuel E Marsh; Beth Stevens
Journal:  Immunity       Date:  2019-04-16       Impact factor: 31.745

Review 8.  Pro-cathepsin D, Prosaposin, and Progranulin: Lysosomal Networks in Parkinsonism.

Authors:  Nahid Tayebi; Grisel Lopez; Jenny Do; Ellen Sidransky
Journal:  Trends Mol Med       Date:  2020-09-15       Impact factor: 11.951

9.  The endocytic membrane trafficking pathway plays a major role in the risk of Parkinson's disease.

Authors:  Sara Bandres-Ciga; Sara Saez-Atienzar; Luis Bonet-Ponce; Kimberley Billingsley; Dan Vitale; Cornelis Blauwendraat; Jesse Raphael Gibbs; Lasse Pihlstrøm; Ziv Gan-Or; Mark R Cookson; Mike A Nalls; Andrew B Singleton
Journal:  Mov Disord       Date:  2019-01-24       Impact factor: 10.338

10.  The Genetic Architecture of Parkinson Disease in Spain: Characterizing Population-Specific Risk, Differential Haplotype Structures, and Providing Etiologic Insight.

Authors:  Sara Bandres-Ciga; Sarah Ahmed; Marya S Sabir; Cornelis Blauwendraat; Astrid D Adarmes-Gómez; Inmaculada Bernal-Bernal; Marta Bonilla-Toribio; Dolores Buiza-Rueda; Fátima Carrillo; Mario Carrión-Claro; Pilar Gómez-Garre; Silvia Jesús; Miguel A Labrador-Espinosa; Daniel Macias; Carlota Méndez-Del-Barrio; Teresa Periñán-Tocino; Cristina Tejera-Parrado; Laura Vargas-González; Monica Diez-Fairen; Ignacio Alvarez; Juan Pablo Tartari; Mariateresa Buongiorno; Miquel Aguilar; Ana Gorostidi; Jesús Alberto Bergareche; Elisabet Mondragon; Ana Vinagre-Aragon; Ioana Croitoru; Javier Ruiz-Martínez; Oriol Dols-Icardo; Jaime Kulisevsky; Juan Marín-Lahoz; Javier Pagonabarraga; Berta Pascual-Sedano; Mario Ezquerra; Ana Cámara; Yaroslau Compta; Manel Fernández; Rubén Fernández-Santiago; Esteban Muñoz; Eduard Tolosa; Francesc Valldeoriola; Isabel Gonzalez-Aramburu; Antonio Sanchez Rodriguez; María Sierra; Manuel Menéndez-González; Marta Blazquez; Ciara Garcia; Esther Suarez-San Martin; Pedro García-Ruiz; Juan Carlos Martínez-Castrillo; Lydia Vela-Desojo; Clara Ruz; Francisco Javier Barrero; Francisco Escamilla-Sevilla; Adolfo Mínguez-Castellanos; Debora Cerdan; Cesar Tabernero; Maria Jose Gomez Heredia; Francisco Perez Errazquin; Manolo Romero-Acebal; Cici Feliz; Jose Luis Lopez-Sendon; Marina Mata; Irene Martínez Torres; Jonggeol Jeffrey Kim; Clifton L Dalgard; Janet Brooks; Sara Saez-Atienzar; J Raphael Gibbs; Rafael Jorda; Juan A Botia; Luis Bonet-Ponce; Karen E Morrison; Carl Clarke; Manuela Tan; Huw Morris; Connor Edsall; Dena Hernandez; Javier Simon-Sanchez; Mike A Nalls; Sonja W Scholz; Adriano Jimenez-Escrig; Jacinto Duarte; Francisco Vives; Raquel Duran; Janet Hoenicka; Victoria Alvarez; Jon Infante; Maria José Marti; Jordi Clarimón; Adolfo López de Munain; Pau Pastor; Pablo Mir; Andrew Singleton
Journal:  Mov Disord       Date:  2019-10-29       Impact factor: 10.338

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.